provider portal
Wesper Journal
Zepbound (tirzepatide) has received FDA approval for the treatment of obstructive sleep apnea, now included in Medicare coverage to help manage the condition alongside obesity. This approval marks a shift towards a holistic approach, combining medication with real-time monitoring for...
Continue reading
GLP-1 therapies, such as Zepbound (tirzepatide), address obstructive sleep apnea by aiding weight management, thereby reducing airway pressure and improving respiratory health. Wesper's wearable technology enhances treatment by providing continuous monitoring, allowing for timely adjustments to therapy plans. FDA’s Landmark...
Continue reading
Obstructive sleep apnea (OSA) has been linked to an increased risk of cancer, with individuals suffering from OSA being 1.53 times more likely to receive a cancer diagnosis. The mechanisms involve intermittent hypoxia and inflammation, which can foster an environment...
Continue reading
Discover the intricate link between diabetes and sleep apnea in this insightful article. Learn how obstructive sleep apnea (OSA) significantly raises the risk of developing type 2 diabetes, with over half of diabetic individuals also suffering from OSA. Explore the shared risk factors, the impact of sleep apnea on glucose metabolism, and why early screening is crucial for effective management. This comprehensive guide offers valuable strategies for integrating lifestyle changes, screening, and innovative treatments like CPAP therapy to improve health outcomes for those affected by both conditions.
Continue reading
Discover how undiagnosed sleep apnea accelerates aging by triggering epigenetic changes that heighten mortality risk and chronic disease. Learn how CPAP therapy can slow or reverse this process, enhancing longevity and quality of life.
Continue reading
